Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tyroserleutide

Drug Profile

Tyroserleutide

Alternative Names: CMS-024; YSL

Latest Information Update: 11 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator China Medical System
  • Class Antineoplastics; Oligopeptides
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Liver cancer

Most Recent Events

  • 19 Jan 2012 Tyroserleutide is available for licensing as of 31 Dec 2010. http://en.cms.net.cn/
  • 31 Jul 2011 Phase-III clinical trials in liver cancer (combination therapy, adjuvant therapy) in China (IV)
  • 31 Jan 2008 China's SFDA has asked for further clinical data before approval can be given for tyroserleutide for unresectable primary liver carcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top